June 10, 2020—Randox Laboratories ToRCH quality controls for infectious disease testing in newborns have been granted the CE mark.
Manufactured from human plasma, the multianalyte controls are designed to react to the test system in the same manner as patient samples, aiming to help laboratories meet ISO 15189:2012 for quality and competence.
“The CE marking of the ToRCH controls from Randox will be a game-changer for clinicians and patients alike, by facilitating early, accurate, and comprehensive diagnoses of infectious diseases in newborns that allow for the best possible patient outcomes,” Lynsey Adams, Randox quality control manager, said in a press release. “Unlike analyzer-specific tests, these controls can be used across a wide range of laboratory technologies and complement our already existing RIQAS Serology EQA programs to provide laboratories with a complete QC solution from a single supplier.”
The controls are provided in a liquid, ready-to-use format and have a working stability of 60 days at 2°C to 8°C.